Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LTI 03 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms RENEW
  • Sponsors Rein Therapeutics

Most Recent Events

  • 30 Apr 2026 According to a Rein Therapeutics media release, company announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of 1.00 dollar per share for aggregate gross proceeds of 50 million dollars, the proceeds are intended to fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis.
  • 29 Apr 2026 According to a Rein Therapeutics media release, the company has enrolled 8 patients in trial to date, with 2 additional patients expected to be enrolled this week.
  • 03 Mar 2026 According to a Rein Therapeutics media release, the first patient has been dosed in the trial. And, company expects to enroll patients through mid-2027, with interim data anticipated in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top